Bioassay of clonitralid for possible carcinogenicity.

{"title":"Bioassay of clonitralid for possible carcinogenicity.","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A bioassay for possible carcinogenicity of clonitralid was conducted using Osborne-Mendel rats and B6C3F1 mice. Clonitralid was administered in the feed, at either of two concentrations, to groups of 50 male and 50 female animals of each species. Twenty animals of each sex and species were placed on test as controls. The time-weighted average high and low dietary concentrations of clonitralid were, respectively, 28,433 and 14,216 ppm for rats and 549 and 274 ppm for mice. After a 78-week period of compound administration, there was an additional observation period of 32 to 33 weeks for rats and 13 to 14 weeks for mice. Adequate numbers of male rats, female rats, and female mice survived long enough to be at risk from late-developing tumors. Because of inadequate survival among male mice, however, results obtained from observation of the male mouse groups cannot be considered conclusive. The incidences of mammary adenocarcinomas in treated female rats were not significantly higher than the incidences observed in control female rats. However, the incidences of this lesion in dosed female rats were greater than or equal to 22 percent, while the highest incidence observed in 15 control groups at this laboratory was only 10 percent with a mean incidence of 2.6 percent. The occurrence in high dose female rats (2/45) of carcinomas in the glandular portion of the stomach with metastases to other sites was not statistically significant. This incidence, however, is much greater than the historical control incidence and suggests an association between administration of clonitralid and the development of these tumors. No statistically significant increased tumor incidences were observed among male rats or mice of either sex dosed with clonitralid. Under the conditions of this bioassay, there was no convincing evidence that clonitralid was carcinogenic to Osborne-Mendel rats or to female B6C3F1 mice. Poor survival of male mice did not permit an evaluation of carcinogenicity in these animals.</p>","PeriodicalId":18935,"journal":{"name":"National Cancer Institute carcinogenesis technical report series","volume":"91 ","pages":"1-105"},"PeriodicalIF":0.0000,"publicationDate":"1978-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"National Cancer Institute carcinogenesis technical report series","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A bioassay for possible carcinogenicity of clonitralid was conducted using Osborne-Mendel rats and B6C3F1 mice. Clonitralid was administered in the feed, at either of two concentrations, to groups of 50 male and 50 female animals of each species. Twenty animals of each sex and species were placed on test as controls. The time-weighted average high and low dietary concentrations of clonitralid were, respectively, 28,433 and 14,216 ppm for rats and 549 and 274 ppm for mice. After a 78-week period of compound administration, there was an additional observation period of 32 to 33 weeks for rats and 13 to 14 weeks for mice. Adequate numbers of male rats, female rats, and female mice survived long enough to be at risk from late-developing tumors. Because of inadequate survival among male mice, however, results obtained from observation of the male mouse groups cannot be considered conclusive. The incidences of mammary adenocarcinomas in treated female rats were not significantly higher than the incidences observed in control female rats. However, the incidences of this lesion in dosed female rats were greater than or equal to 22 percent, while the highest incidence observed in 15 control groups at this laboratory was only 10 percent with a mean incidence of 2.6 percent. The occurrence in high dose female rats (2/45) of carcinomas in the glandular portion of the stomach with metastases to other sites was not statistically significant. This incidence, however, is much greater than the historical control incidence and suggests an association between administration of clonitralid and the development of these tumors. No statistically significant increased tumor incidences were observed among male rats or mice of either sex dosed with clonitralid. Under the conditions of this bioassay, there was no convincing evidence that clonitralid was carcinogenic to Osborne-Mendel rats or to female B6C3F1 mice. Poor survival of male mice did not permit an evaluation of carcinogenicity in these animals.

氯硝唑可能致癌性的生物测定。
用奥斯本-孟德尔大鼠和B6C3F1小鼠进行了氯硝基胺可能致癌性的生物测定。将氯硝唑以两种浓度中的任意一种加入饲料中,每组50只雄性和50只雌性动物。各性别、各物种各20只作为对照进行试验。大鼠饮食中氯硝唑的时间加权平均高、低浓度分别为28,433和14,216 ppm,小鼠为549和274 ppm。复方给药78周后,大鼠和小鼠的观察期分别为32 ~ 33周和13 ~ 14周。有足够数量的雄性大鼠、雌性大鼠和雌性小鼠存活了足够长的时间,从而有罹患晚期肿瘤的风险。然而,由于雄性小鼠的存活率不足,从雄性小鼠组的观察结果不能被认为是结论性的。雌性大鼠乳腺腺癌的发生率与对照组相比无明显差异。然而,雌性大鼠的这种病变发生率大于或等于22%,而在本实验室的15个对照组中观察到的最高发病率仅为10%,平均发病率为2.6%。高剂量雌性大鼠胃腺部癌转移发生率(2/45)无统计学意义。然而,这一发病率远高于历史对照发病率,表明氯硝唑的使用与这些肿瘤的发展之间存在关联。在服用氯硝唑的雄性大鼠或小鼠中,没有观察到有统计学意义的肿瘤发生率增加。在本实验条件下,没有令人信服的证据表明氯硝基胺对奥斯本-孟德尔大鼠或雌性B6C3F1小鼠具有致癌性。雄性小鼠存活率低,无法对这些动物的致癌性进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信